Jill M. Broadfoot is the Chief Financial Officer at aTyr Pharma Inc., a clinical-stage biotechnology company developing innovative therapies for severe respiratory diseases, including its lead candidate efzofitimod for pulmonary sarcoidosis and interstitial lung disease. With more than 20 years of finance leadership in the biotechnology and pharmaceutical sectors, Jill has a proven track record of guiding companies through complex financial landscapes, from early-stage development to commercialization. Prior to joining aTyr Pharma in April 2021, Jill served as CFO at Zosano Pharma, where she managed financial operations, SEC reporting, and strategic initiatives during a pivotal merger. She previously held the role of Vice President of Finance at Relypsa, Inc., playing a key role in its $1.3 billion acquisition by Gilead Sciences in 2016. Earlier positions include Director of Financial Planning and Analysis at Jazz Pharmaceuticals and various senior finance roles at biotech firms, where she excelled in capital raising, investor relations, and operational efficiency. In her current role at aTyr Pharma, Jill oversees all financial functions, including budgeting, treasury, accounting, and capital markets activities. Her expertise has been instrumental in securing funding for clinical programs, optimizing resource allocation, and enhancing shareholder value amid advancing pipeline milestones. A Certified Public Accountant, Jill holds a B.S. in Business Administration from the University of California, Davis.